2011
DOI: 10.1152/japplphysiol.00117.2011
|View full text |Cite
|
Sign up to set email alerts
|

Differences in serotoninergic metabolism possibly contribute to differences in breathing phenotype of FVB/N and C57BL/6J mice

Abstract: Mouse readiness for gene manipulation allowed the production of mutants with breathing defects reminiscent of breathing syndromes. As C57BL/6J and FVB/N inbred strains were often used as background strains for producing mutants, we compared their breathing pattern from birth onwards. At birth, in vivo and in vitro approaches revealed robust respiratory rhythm in FVB/N, but not C57BL/6J, neonates. With aging, rhythm robustness difference persisted, and interstrain differences in tidal volume, minute ventilation… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

2
14
0

Year Published

2011
2011
2018
2018

Publication Types

Select...
7
1

Relationship

2
6

Authors

Journals

citations
Cited by 14 publications
(16 citation statements)
references
References 64 publications
2
14
0
Order By: Relevance
“…These mice have a significantly lower pCO 2 than C57BL/6 mice anesthetized under the same conditions (Supplementary Figure S3) and a trend toward a lower arterial pH. 12 In keeping with this, we maintained endtidal pCO 2 at values~20 to 30 mm Hg, which correspond to an arterial pH of 30 to 40 mm Hg, i.e., the physiologic value for FVB/N mice.…”
Section: Resultsmentioning
confidence: 69%
“…These mice have a significantly lower pCO 2 than C57BL/6 mice anesthetized under the same conditions (Supplementary Figure S3) and a trend toward a lower arterial pH. 12 In keeping with this, we maintained endtidal pCO 2 at values~20 to 30 mm Hg, which correspond to an arterial pH of 30 to 40 mm Hg, i.e., the physiologic value for FVB/N mice.…”
Section: Resultsmentioning
confidence: 69%
“…Conversely, bigenic GSK3α.KOxTau.P301L mice (detailed below) did not survive longer than the parental Tau.P301L mice, notwithstanding an initial delay in precocious mortality (Figure  3B, arched area) [29,35]. Terminal Tau.P301L mice present with a rapid progression (2–3 weeks) of motor defects and loss in body-weight, upper-airway dysfunction with asphyxia and exhaustion, terminating in precocious death between age 8 and 11 months (mean 9.5 mo) [29,35-37]. The current data imply that GSK3α did not affect this terminal phase, but contributed negatively to the early phenotype of Tau.P301L mice, characterized by defective cognition and beginning motor problems [29,35,36].…”
Section: Resultsmentioning
confidence: 72%
“…Besides age of onset, both models present regional differences in their intensity of eventual tauopathy [26], [27], [29], [46][50]. Nevertheless, the terminal phase was very similar in both models, despite the age difference, by combination of clinical indices that progress rapidly (2–3 weeks) leading to death: reduction in bodyweight, increased clasping of hind- and then fore-limbs, hyperkyphosis and inactivity, upper airway dysfunction caused by defective brainstem circuits [46], [50], [51]. The endpoint was invariably precocious death, for Tau.P301L mice mostly between age 8–12 months (average 9 months) without survivors beyond age 12 months [29].…”
Section: Resultsmentioning
confidence: 97%
“…The endpoint was invariably precocious death, for Tau.P301L mice mostly between age 8–12 months (average 9 months) without survivors beyond age 12 months [29]. The age of death of biGT mice was less sharply defined, ranging from 10 to 22 months [26], [27], [46], [50], [51]. The mechanistic contributions of GSK3β in the biGT model to the delay in tauopathy and to clinical phenotype are subject of ongoing studies.…”
Section: Resultsmentioning
confidence: 99%